View ValuationSprint Bioscience 将来の成長Future 基準チェック /16 Sprint Bioscienceは収益が増加すると予測されています。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長25.5%収益成長率3.6%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日19 May 2026今後の成長に関する最新情報Price Target Changed • Jun 02Price target decreased by 33% to kr2.00Down from kr3.00, the current price target is provided by 1 analyst. New target price is 389% above last closing price of kr0.41. Stock is down 67% over the past year. The company posted a net loss per share of kr0.26 last year.Price Target Changed • Feb 15Price target increased by 10% to kr3.20Up from kr2.90, the current price target is provided by 1 analyst. New target price is 110% above last closing price of kr1.52. Stock is up 69% over the past year.Price Target Changed • Nov 16Price target decreased to kr3.30Down from kr16.05, the current price target is provided by 1 analyst. New target price is 360% above last closing price of kr0.72. Stock is down 86% over the past year. The company posted a net loss per share of kr0.85 last year.Breakeven Date Change • Apr 27Forecast to breakeven in 2023The analyst covering Sprint Bioscience expects the company to break even for the first time. New forecast suggests the company will make a profit of kr5.00m in 2023. Average annual earnings growth of 79% is required to achieve expected profit on schedule.すべての更新を表示Recent updatesReported Earnings • May 19First quarter 2026 earnings released: kr0.12 loss per share (vs kr0.081 loss in 1Q 2025)First quarter 2026 results: kr0.12 loss per share (further deteriorated from kr0.081 loss in 1Q 2025). Revenue: kr53.0k (down 100% from 1Q 2025). Net loss: kr12.9m (loss widened 129% from 1Q 2025). Revenue is forecast to grow 3.6% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 92% per year but the company’s share price has only increased by 73% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • May 07Investor sentiment improves as stock rises 18%After last week's 18% share price gain to kr3.67, the stock trades at a trailing P/E ratio of 4.2x. Average trailing P/E is 29x in the Biotechs industry in Sweden. Total returns to shareholders of 474% over the past three years.Valuation Update With 7 Day Price Move • Apr 15Investor sentiment improves as stock rises 31%After last week's 31% share price gain to kr3.87, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 19x in the Biotechs industry in Sweden. Total returns to shareholders of 465% over the past three years.New Risk • Apr 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Minor Risk Market cap is less than US$100m (kr348.2m market cap, or US$37.6m).お知らせ • Apr 10Sprint Bioscience AB (publ), Annual General Meeting, May 13, 2026Sprint Bioscience AB (publ), Annual General Meeting, May 13, 2026, at 15:00 W. Europe Standard Time. Location: sprint biosciences premises at novum, halsovagen 7, 141 57 huddinge, SwedenValuation Update With 7 Day Price Move • Mar 31Investor sentiment improves as stock rises 21%After last week's 21% share price gain to kr2.38, the stock trades at a trailing P/E ratio of 2.7x. Average trailing P/E is 17x in the Biotechs industry in Sweden. Total returns to shareholders of 236% over the past three years.お知らせ • Mar 18Sprint Bioscience AB (publ) Presents New Preclinical Data On Dcps Program At The Aacr Annual MeetingSprint Bioscience AB (publ) announced that new preclinical data from the company’s DCPS program will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place on April 17, 2026, in San Diego, USA. The poster presentation summarizes new research findings supporting DCPS inhibition as a valid therapeutic strategy for patients with acute myeloid leukemia (AML). The results deepen the scientific understanding of DCPS biology and highlights its potential to improve patient stratification in AML. The poster “Integrated FHIT and IDH2 biomarkers predict synthetic lethal response to DCPS inhibition in acute myeloid leukemia” will be presented by Madhurendra Singh, Associate Principal Scientist at Sprint Bioscience.Valuation Update With 7 Day Price Move • Feb 18Investor sentiment improves as stock rises 26%After last week's 26% share price gain to kr2.14, the stock trades at a trailing P/E ratio of 2.5x. Average trailing P/E is 29x in the Biotechs industry in Sweden. Total returns to shareholders of 269% over the past three years.New Risk • Jan 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr39m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr39m free cash flow). Share price has been highly volatile over the past 3 months (34% average weekly change). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Minor Risk Market cap is less than US$100m (kr155.1m market cap, or US$16.8m).Recent Insider Transactions • Dec 02Independent Chairman of the Board recently bought kr95k worth of stockOn the 28th of November, Bjorn Sjostrand bought around 60k shares on-market at roughly kr1.59 per share. This transaction amounted to 6.8% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Bjorn's only on-market trade for the last 12 months.Reported Earnings • Nov 26Third quarter 2025 earnings released: kr0.08 loss per share (vs kr0.075 loss in 3Q 2024)Third quarter 2025 results: kr0.08 loss per share (further deteriorated from kr0.075 loss in 3Q 2024). Revenue: kr5.27m (down 64% from 3Q 2024). Net loss: kr8.42m (loss widened 62% from 3Q 2024). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has only increased by 36% per year, which means it is significantly lagging earnings growth.Reported Earnings • Aug 27Second quarter 2025 earnings released: kr0.083 loss per share (vs kr0.083 loss in 2Q 2024)Second quarter 2025 results: kr0.083 loss per share (in line with 2Q 2024). Revenue: kr14.2m (down 15% from 2Q 2024). Net loss: kr7.37m (loss widened 28% from 2Q 2024). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.Price Target Changed • Jun 02Price target decreased by 33% to kr2.00Down from kr3.00, the current price target is provided by 1 analyst. New target price is 389% above last closing price of kr0.41. Stock is down 67% over the past year. The company posted a net loss per share of kr0.26 last year.Reported Earnings • May 28First quarter 2025 earnings released: kr0.081 loss per share (vs kr0.044 loss in 1Q 2024)First quarter 2025 results: kr0.081 loss per share (further deteriorated from kr0.044 loss in 1Q 2024). Revenue: kr14.3m (down 20% from 1Q 2024). Net loss: kr5.64m (loss widened 84% from 1Q 2024). Revenue is forecast to grow 1.2% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings.New Risk • May 18New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 51% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Market cap is less than US$10m (kr46.3m market cap, or US$4.73m).お知らせ • Apr 05Sprint Bioscience AB (publ), Annual General Meeting, May 07, 2025Sprint Bioscience AB (publ), Annual General Meeting, May 07, 2025, at 15:00 W. Europe Standard Time. Location: at sprint bioscience`s, premises, at novum SwedenReported Earnings • Feb 16Full year 2024 earnings released: kr0.26 loss per share (vs kr0.006 loss in FY 2023)Full year 2024 results: kr0.26 loss per share (further deteriorated from kr0.006 loss in FY 2023). Revenue: kr67.4m (up 31% from FY 2023). Net loss: kr18.3m (loss widened kr17.8m from FY 2023). Revenue is forecast to grow 1.2% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.Price Target Changed • Feb 15Price target increased by 10% to kr3.20Up from kr2.90, the current price target is provided by 1 analyst. New target price is 110% above last closing price of kr1.52. Stock is up 69% over the past year.お知らせ • Dec 18Sprint Bioscience AB (Publ) Adds New Cancer Drug Program to PortfolioSprint Bioscience AB (publ) announced that the company is broadening its portfolio with a drug development program for the treatment of acute myeloid leukemia (AML). The program targets the decapping scavenger enzyme (DCPS), a target protein that has been validated both in scientific literature and by Sprint Bioscience in collaboration with Associate Professor Julian Walfridsson at Karolinska Institutet. The initiation of Sprint Bioscience's DCPS program is part of the company's strategy to capitalize on its platform for small-molecule drug discovery to broaden the portfolio in the cancer area and to bring more opportunities for future licensing deals. The DCPS program focuses on a target protein that degrades a metabolite resulting from the processing of mRNA. Both small-molecule inhibition and genetic knock-down of DCPS affects the differentiation and proliferation of several AML cell lines as well as patient-derived samples. Furthermore, healthy tissue seems to be insensitive to DCPS inhibition, indicating that DCPS inhibitors could offer a safe and effective treatment option for AML patients. Sprint Bioscience has also identified biomarkers to predict response to DCPS inhibition, enabling patient selection and clinical success for patients with unmet therapeutic needs. AML is a severe type of blood cancer. The Global Burden of Disease study estimates that about 140,000 people around the world are diagnosed with AML on a yearly basis. There is an urgent medical need to identify safe and effective therapies to improve treatment outcomes. Sprint Bioscience's portfolio now consists of six internal drug development programs (five of which are in cancer) and one program that has been licensed to Day One Biopharmaceuticals.New Risk • Dec 04New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (kr121.5m market cap, or US$11.0m).New Risk • Nov 19New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr103.1m (US$9.38m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (kr103.1m market cap, or US$9.38m). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).Reported Earnings • Nov 01Third quarter 2024 earnings released: kr0.075 loss per share (vs kr0.41 profit in 3Q 2023)Third quarter 2024 results: kr0.075 loss per share (down from kr0.41 profit in 3Q 2023). Revenue: kr14.8m (down 63% from 3Q 2023). Net loss: kr5.21m (down 118% from profit in 3Q 2023). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Oct 18Investor sentiment improves as stock rises 24%After last week's 24% share price gain to kr1.78, the stock trades at a trailing P/E ratio of 8.4x. Average trailing P/E is 48x in the Biotechs industry in Sweden. Total loss to shareholders of 64% over the past three years.Valuation Update With 7 Day Price Move • Aug 06Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to kr1.20, the stock trades at a trailing P/E ratio of 9.5x. Average trailing P/E is 43x in the Biotechs industry in Sweden. Total loss to shareholders of 80% over the past three years.Valuation Update With 7 Day Price Move • Jun 12Investor sentiment improves as stock rises 17%After last week's 17% share price gain to kr1.52, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 26x in the Biotechs industry in Europe. Total loss to shareholders of 83% over the past three years.Reported Earnings • Feb 16Full year 2023 earnings released: kr0.006 loss per share (vs kr1.43 loss in FY 2022)Full year 2023 results: kr0.006 loss per share (improved from kr1.43 loss in FY 2022). Revenue: kr54.3m (up kr54.2m from FY 2022). Net loss: kr438.0k (loss narrowed 99% from FY 2022). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.Reported Earnings • Oct 27Third quarter 2023 earnings released: EPS: kr0.41 (vs kr0.33 loss in 3Q 2022)Third quarter 2023 results: EPS: kr0.41 (up from kr0.33 loss in 3Q 2022). Revenue: kr41.2m (up kr41.2m from 3Q 2022). Net income: kr28.6m (up kr41.9m from 3Q 2022). Profit margin: 70% (up from net loss in 3Q 2022). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 28Second quarter 2023 earnings released: kr0.17 loss per share (vs kr0.45 loss in 2Q 2022)Second quarter 2023 results: kr0.17 loss per share (improved from kr0.45 loss in 2Q 2022). Net loss: kr11.7m (loss narrowed 35% from 2Q 2022). Revenue is forecast to grow 51% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.分析記事 • Jun 12Estimating The Fair Value Of Sprint Bioscience AB (publ) (STO:SPRINT)Key Insights The projected fair value for Sprint Bioscience is kr0.77 based on 2 Stage Free Cash Flow to Equity Current...Buying Opportunity • May 30Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 3.4%. The fair value is estimated to be kr0.77, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 31% over the last 3 years. Earnings per share has grown by 35%.Buying Opportunity • Mar 13Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 8.9%. The fair value is estimated to be kr0.66, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 22% over the last 3 years. Earnings per share has grown by 31%.分析記事 • Feb 19A Look At The Intrinsic Value Of Sprint Bioscience AB (publ) (STO:SPRINT)Does the February share price for Sprint Bioscience AB (publ) ( STO:SPRINT ) reflect what it's really worth? Today, we...Reported Earnings • Feb 17Full year 2022 earnings released: kr1.43 loss per share (vs kr0.85 loss in FY 2021)Full year 2022 results: kr1.43 loss per share (further deteriorated from kr0.85 loss in FY 2021). Net loss: kr60.2m (loss widened 140% from FY 2021). Revenue is forecast to grow 48% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 60% per year, which means it is significantly lagging earnings.Price Target Changed • Nov 16Price target decreased to kr3.30Down from kr16.05, the current price target is provided by 1 analyst. New target price is 360% above last closing price of kr0.72. Stock is down 86% over the past year. The company posted a net loss per share of kr0.85 last year.Reported Earnings • Oct 30Third quarter 2022 earnings released: kr0.33 loss per share (vs kr0.54 profit in 3Q 2021)Third quarter 2022 results: kr0.33 loss per share (down from kr0.54 profit in 3Q 2021). Net loss: kr13.3m (down 176% from profit in 3Q 2021). Revenue is forecast to grow 79% p.a. on average during the next 3 years, compared to a 27% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 24Second quarter 2022 earnings released: kr0.45 loss per share (vs kr0.60 loss in 2Q 2021)Second quarter 2022 results: kr0.45 loss per share. Revenue: kr24.0k (up 100% from 2Q 2021). Net loss: kr17.9m (loss widened 29% from 2Q 2021).Reported Earnings • May 13First quarter 2022 earnings: EPS misses analyst expectationsFirst quarter 2022 results: kr0.36 loss per share. Revenue: kr53.0k (down 87% from 1Q 2021). Net loss: kr14.2m (loss widened 3.7% from 1Q 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 6.2%.Breakeven Date Change • Apr 27Forecast to breakeven in 2023The analyst covering Sprint Bioscience expects the company to break even for the first time. New forecast suggests the company will make a profit of kr5.00m in 2023. Average annual earnings growth of 79% is required to achieve expected profit on schedule.Board Change • Apr 27High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Director Rune Nordlander is the most experienced director on the board, commencing their role in 2010. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 18Full year 2021 earnings: EPS misses analyst expectationsFull year 2021 results: kr0.85 loss per share (up from kr2.55 loss in FY 2020). Revenue: kr35.0m (up 83% from FY 2020). Net loss: kr25.1m (loss narrowed 41% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 6.2%. Over the next year, revenue is expected to shrink by 5.8% compared to a 216% growth forecast for the pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 17Full year 2021 earnings: EPS exceeds analyst expectationsFull year 2021 results: kr0.85 loss per share (up from kr2.55 loss in FY 2020). Revenue: kr35.1m (up 83% from FY 2020). Net loss: kr25.1m (loss narrowed 41% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 6.3%. Over the next year, revenue is expected to shrink by 5.9% compared to a 213% growth forecast for the pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.Reported Earnings • Oct 29Third quarter 2021 earnings released: EPS kr0.54 (vs kr0.36 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr33.9m (up 399% from 3Q 2020). Net income: kr17.6m (up kr23.6m from 3Q 2020). Profit margin: 52% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Sep 15Director recently bought kr336k worth of stockOn the 10th of September, Rune Nordlander bought around 68k shares on-market at roughly kr4.95 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Reported Earnings • Aug 18Second quarter 2021 earnings released: kr0.60 loss per share (vs kr1.01 loss in 2Q 2020)The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: kr12.0k (down 100% from 2Q 2020). Net loss: kr13.9m (loss widened 11% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.Reported Earnings • May 14First quarter 2021 earnings released: kr0.65 loss per share (vs kr0.79 loss in 1Q 2020)The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: kr408.0k (down 93% from 1Q 2020). Net loss: kr13.7m (loss widened 40% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings.Executive Departure • Mar 03Interim Chief Executive Officer Charlotte Leife has left the companyOn the 1st of March, Charlotte Leife's tenure as Interim Chief Executive Officer of the company ended after less than a year in the role. We don't have any record of a personal shareholding under Charlotte's name. Charlotte is the only executive to leave the company over the last 12 months. Under Charlotte's leadership, the company delivered a total shareholder return of -0.9%.Analyst Estimate Surprise Post Earnings • Feb 20Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 13%. Earnings per share (EPS) also surpassed analyst estimates by 39%. Over the next year, revenue is forecast to grow 62%, compared to a 126% growth forecast for the Biotechs industry in Sweden.Is New 90 Day High Low • Feb 18New 90-day low: kr6.52The company is down 18% from its price of kr8.00 on 20 November 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period.Reported Earnings • Feb 18Full year 2020 earnings released: kr2.02 loss per share (vs kr1.92 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: kr19.6m (down 42% from FY 2019). Net loss: kr42.8m (loss widened 99% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings.Is New 90 Day High Low • Feb 02New 90-day low: kr7.10The company is down 7.0% from its price of kr7.60 on 03 November 2020. The Swedish market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 2.0% over the same period.分析記事 • Nov 19Is Sprint Bioscience (STO:SPRINT) In A Good Position To Deliver On Growth Plans?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Reported Earnings • Nov 02Third quarter 2020 earnings released: kr0.36 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: kr6.79m (up 55% from 3Q 2019). Net loss: kr5.99m (loss narrowed 17% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 28% per year whereas the company’s share price has fallen by 32% per year.業績と収益の成長予測OM:SPRINT - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2027155N/AN/AN/A112/31/202685N/AN/AN/A13/31/2026153847070N/A12/31/2025167928384N/A9/30/202550-26-39-38N/A6/30/202560-22-29-29N/A3/31/202562-21-20-20N/A12/31/202466-18-25-23N/A9/30/202461-19-23-20N/A6/30/202486152124N/A3/31/20247091316N/A12/31/20235202023N/A9/30/202340-101010N/A6/30/20230-52-44-44N/A3/31/20230-58-48-48N/A12/31/20220-60-59-59N/A9/30/20221-60-59-59N/A6/30/202235-30-30-28N/A3/31/202235-26-42-41N/A12/31/202135-25-43-40N/A9/30/202135-25-36-33N/A6/30/20218-48-62-61N/A3/31/202114-47-48-47N/A12/31/202019-43-32-32N/A9/30/202023-39-35-35N/A6/30/202021-40-18-18N/A3/31/202035-23-12-12N/A12/31/201934-22N/A-28N/A9/30/201921-31N/A-35N/A6/30/201919-33N/A-52N/A3/31/20193-47N/A-53N/A12/31/201818-32N/A-29N/A9/30/201831-19N/A-20N/A6/30/201832-15N/A-12N/A3/31/201841-5N/A-7N/A12/31/201733-11N/A-23N/A9/30/201741-1N/A-19N/A6/30/2017475N/A6N/A3/31/2017538N/A7N/A12/31/2016475N/A8N/A9/30/201640-2N/A8N/A6/30/201634-5N/A0N/A3/31/201617-14N/A-1N/A12/31/201513-15N/A1N/A9/30/201510-15N/A2N/A6/30/20156-15N/A-14N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: SPRINTの予測収益成長が 貯蓄率 ( 2% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: SPRINTの収益がSwedish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: SPRINTの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: SPRINTの収益 ( 3.6% ) Swedish市場 ( 0.02% ) よりも速いペースで成長すると予測されています。高い収益成長: SPRINTの収益 ( 3.6% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: SPRINTの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 01:16終値2026/05/21 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sprint Bioscience AB (publ) 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Siri LadowDanske BankFredrik ThorRedeye
Price Target Changed • Jun 02Price target decreased by 33% to kr2.00Down from kr3.00, the current price target is provided by 1 analyst. New target price is 389% above last closing price of kr0.41. Stock is down 67% over the past year. The company posted a net loss per share of kr0.26 last year.
Price Target Changed • Feb 15Price target increased by 10% to kr3.20Up from kr2.90, the current price target is provided by 1 analyst. New target price is 110% above last closing price of kr1.52. Stock is up 69% over the past year.
Price Target Changed • Nov 16Price target decreased to kr3.30Down from kr16.05, the current price target is provided by 1 analyst. New target price is 360% above last closing price of kr0.72. Stock is down 86% over the past year. The company posted a net loss per share of kr0.85 last year.
Breakeven Date Change • Apr 27Forecast to breakeven in 2023The analyst covering Sprint Bioscience expects the company to break even for the first time. New forecast suggests the company will make a profit of kr5.00m in 2023. Average annual earnings growth of 79% is required to achieve expected profit on schedule.
Reported Earnings • May 19First quarter 2026 earnings released: kr0.12 loss per share (vs kr0.081 loss in 1Q 2025)First quarter 2026 results: kr0.12 loss per share (further deteriorated from kr0.081 loss in 1Q 2025). Revenue: kr53.0k (down 100% from 1Q 2025). Net loss: kr12.9m (loss widened 129% from 1Q 2025). Revenue is forecast to grow 3.6% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 92% per year but the company’s share price has only increased by 73% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • May 07Investor sentiment improves as stock rises 18%After last week's 18% share price gain to kr3.67, the stock trades at a trailing P/E ratio of 4.2x. Average trailing P/E is 29x in the Biotechs industry in Sweden. Total returns to shareholders of 474% over the past three years.
Valuation Update With 7 Day Price Move • Apr 15Investor sentiment improves as stock rises 31%After last week's 31% share price gain to kr3.87, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 19x in the Biotechs industry in Sweden. Total returns to shareholders of 465% over the past three years.
New Risk • Apr 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Minor Risk Market cap is less than US$100m (kr348.2m market cap, or US$37.6m).
お知らせ • Apr 10Sprint Bioscience AB (publ), Annual General Meeting, May 13, 2026Sprint Bioscience AB (publ), Annual General Meeting, May 13, 2026, at 15:00 W. Europe Standard Time. Location: sprint biosciences premises at novum, halsovagen 7, 141 57 huddinge, Sweden
Valuation Update With 7 Day Price Move • Mar 31Investor sentiment improves as stock rises 21%After last week's 21% share price gain to kr2.38, the stock trades at a trailing P/E ratio of 2.7x. Average trailing P/E is 17x in the Biotechs industry in Sweden. Total returns to shareholders of 236% over the past three years.
お知らせ • Mar 18Sprint Bioscience AB (publ) Presents New Preclinical Data On Dcps Program At The Aacr Annual MeetingSprint Bioscience AB (publ) announced that new preclinical data from the company’s DCPS program will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place on April 17, 2026, in San Diego, USA. The poster presentation summarizes new research findings supporting DCPS inhibition as a valid therapeutic strategy for patients with acute myeloid leukemia (AML). The results deepen the scientific understanding of DCPS biology and highlights its potential to improve patient stratification in AML. The poster “Integrated FHIT and IDH2 biomarkers predict synthetic lethal response to DCPS inhibition in acute myeloid leukemia” will be presented by Madhurendra Singh, Associate Principal Scientist at Sprint Bioscience.
Valuation Update With 7 Day Price Move • Feb 18Investor sentiment improves as stock rises 26%After last week's 26% share price gain to kr2.14, the stock trades at a trailing P/E ratio of 2.5x. Average trailing P/E is 29x in the Biotechs industry in Sweden. Total returns to shareholders of 269% over the past three years.
New Risk • Jan 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr39m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr39m free cash flow). Share price has been highly volatile over the past 3 months (34% average weekly change). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Minor Risk Market cap is less than US$100m (kr155.1m market cap, or US$16.8m).
Recent Insider Transactions • Dec 02Independent Chairman of the Board recently bought kr95k worth of stockOn the 28th of November, Bjorn Sjostrand bought around 60k shares on-market at roughly kr1.59 per share. This transaction amounted to 6.8% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Bjorn's only on-market trade for the last 12 months.
Reported Earnings • Nov 26Third quarter 2025 earnings released: kr0.08 loss per share (vs kr0.075 loss in 3Q 2024)Third quarter 2025 results: kr0.08 loss per share (further deteriorated from kr0.075 loss in 3Q 2024). Revenue: kr5.27m (down 64% from 3Q 2024). Net loss: kr8.42m (loss widened 62% from 3Q 2024). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has only increased by 36% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 27Second quarter 2025 earnings released: kr0.083 loss per share (vs kr0.083 loss in 2Q 2024)Second quarter 2025 results: kr0.083 loss per share (in line with 2Q 2024). Revenue: kr14.2m (down 15% from 2Q 2024). Net loss: kr7.37m (loss widened 28% from 2Q 2024). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.
Price Target Changed • Jun 02Price target decreased by 33% to kr2.00Down from kr3.00, the current price target is provided by 1 analyst. New target price is 389% above last closing price of kr0.41. Stock is down 67% over the past year. The company posted a net loss per share of kr0.26 last year.
Reported Earnings • May 28First quarter 2025 earnings released: kr0.081 loss per share (vs kr0.044 loss in 1Q 2024)First quarter 2025 results: kr0.081 loss per share (further deteriorated from kr0.044 loss in 1Q 2024). Revenue: kr14.3m (down 20% from 1Q 2024). Net loss: kr5.64m (loss widened 84% from 1Q 2024). Revenue is forecast to grow 1.2% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings.
New Risk • May 18New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 51% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Market cap is less than US$10m (kr46.3m market cap, or US$4.73m).
お知らせ • Apr 05Sprint Bioscience AB (publ), Annual General Meeting, May 07, 2025Sprint Bioscience AB (publ), Annual General Meeting, May 07, 2025, at 15:00 W. Europe Standard Time. Location: at sprint bioscience`s, premises, at novum Sweden
Reported Earnings • Feb 16Full year 2024 earnings released: kr0.26 loss per share (vs kr0.006 loss in FY 2023)Full year 2024 results: kr0.26 loss per share (further deteriorated from kr0.006 loss in FY 2023). Revenue: kr67.4m (up 31% from FY 2023). Net loss: kr18.3m (loss widened kr17.8m from FY 2023). Revenue is forecast to grow 1.2% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
Price Target Changed • Feb 15Price target increased by 10% to kr3.20Up from kr2.90, the current price target is provided by 1 analyst. New target price is 110% above last closing price of kr1.52. Stock is up 69% over the past year.
お知らせ • Dec 18Sprint Bioscience AB (Publ) Adds New Cancer Drug Program to PortfolioSprint Bioscience AB (publ) announced that the company is broadening its portfolio with a drug development program for the treatment of acute myeloid leukemia (AML). The program targets the decapping scavenger enzyme (DCPS), a target protein that has been validated both in scientific literature and by Sprint Bioscience in collaboration with Associate Professor Julian Walfridsson at Karolinska Institutet. The initiation of Sprint Bioscience's DCPS program is part of the company's strategy to capitalize on its platform for small-molecule drug discovery to broaden the portfolio in the cancer area and to bring more opportunities for future licensing deals. The DCPS program focuses on a target protein that degrades a metabolite resulting from the processing of mRNA. Both small-molecule inhibition and genetic knock-down of DCPS affects the differentiation and proliferation of several AML cell lines as well as patient-derived samples. Furthermore, healthy tissue seems to be insensitive to DCPS inhibition, indicating that DCPS inhibitors could offer a safe and effective treatment option for AML patients. Sprint Bioscience has also identified biomarkers to predict response to DCPS inhibition, enabling patient selection and clinical success for patients with unmet therapeutic needs. AML is a severe type of blood cancer. The Global Burden of Disease study estimates that about 140,000 people around the world are diagnosed with AML on a yearly basis. There is an urgent medical need to identify safe and effective therapies to improve treatment outcomes. Sprint Bioscience's portfolio now consists of six internal drug development programs (five of which are in cancer) and one program that has been licensed to Day One Biopharmaceuticals.
New Risk • Dec 04New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (kr121.5m market cap, or US$11.0m).
New Risk • Nov 19New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr103.1m (US$9.38m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (kr103.1m market cap, or US$9.38m). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).
Reported Earnings • Nov 01Third quarter 2024 earnings released: kr0.075 loss per share (vs kr0.41 profit in 3Q 2023)Third quarter 2024 results: kr0.075 loss per share (down from kr0.41 profit in 3Q 2023). Revenue: kr14.8m (down 63% from 3Q 2023). Net loss: kr5.21m (down 118% from profit in 3Q 2023). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Oct 18Investor sentiment improves as stock rises 24%After last week's 24% share price gain to kr1.78, the stock trades at a trailing P/E ratio of 8.4x. Average trailing P/E is 48x in the Biotechs industry in Sweden. Total loss to shareholders of 64% over the past three years.
Valuation Update With 7 Day Price Move • Aug 06Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to kr1.20, the stock trades at a trailing P/E ratio of 9.5x. Average trailing P/E is 43x in the Biotechs industry in Sweden. Total loss to shareholders of 80% over the past three years.
Valuation Update With 7 Day Price Move • Jun 12Investor sentiment improves as stock rises 17%After last week's 17% share price gain to kr1.52, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 26x in the Biotechs industry in Europe. Total loss to shareholders of 83% over the past three years.
Reported Earnings • Feb 16Full year 2023 earnings released: kr0.006 loss per share (vs kr1.43 loss in FY 2022)Full year 2023 results: kr0.006 loss per share (improved from kr1.43 loss in FY 2022). Revenue: kr54.3m (up kr54.2m from FY 2022). Net loss: kr438.0k (loss narrowed 99% from FY 2022). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.
Reported Earnings • Oct 27Third quarter 2023 earnings released: EPS: kr0.41 (vs kr0.33 loss in 3Q 2022)Third quarter 2023 results: EPS: kr0.41 (up from kr0.33 loss in 3Q 2022). Revenue: kr41.2m (up kr41.2m from 3Q 2022). Net income: kr28.6m (up kr41.9m from 3Q 2022). Profit margin: 70% (up from net loss in 3Q 2022). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 28Second quarter 2023 earnings released: kr0.17 loss per share (vs kr0.45 loss in 2Q 2022)Second quarter 2023 results: kr0.17 loss per share (improved from kr0.45 loss in 2Q 2022). Net loss: kr11.7m (loss narrowed 35% from 2Q 2022). Revenue is forecast to grow 51% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.
分析記事 • Jun 12Estimating The Fair Value Of Sprint Bioscience AB (publ) (STO:SPRINT)Key Insights The projected fair value for Sprint Bioscience is kr0.77 based on 2 Stage Free Cash Flow to Equity Current...
Buying Opportunity • May 30Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 3.4%. The fair value is estimated to be kr0.77, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 31% over the last 3 years. Earnings per share has grown by 35%.
Buying Opportunity • Mar 13Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 8.9%. The fair value is estimated to be kr0.66, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 22% over the last 3 years. Earnings per share has grown by 31%.
分析記事 • Feb 19A Look At The Intrinsic Value Of Sprint Bioscience AB (publ) (STO:SPRINT)Does the February share price for Sprint Bioscience AB (publ) ( STO:SPRINT ) reflect what it's really worth? Today, we...
Reported Earnings • Feb 17Full year 2022 earnings released: kr1.43 loss per share (vs kr0.85 loss in FY 2021)Full year 2022 results: kr1.43 loss per share (further deteriorated from kr0.85 loss in FY 2021). Net loss: kr60.2m (loss widened 140% from FY 2021). Revenue is forecast to grow 48% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 60% per year, which means it is significantly lagging earnings.
Price Target Changed • Nov 16Price target decreased to kr3.30Down from kr16.05, the current price target is provided by 1 analyst. New target price is 360% above last closing price of kr0.72. Stock is down 86% over the past year. The company posted a net loss per share of kr0.85 last year.
Reported Earnings • Oct 30Third quarter 2022 earnings released: kr0.33 loss per share (vs kr0.54 profit in 3Q 2021)Third quarter 2022 results: kr0.33 loss per share (down from kr0.54 profit in 3Q 2021). Net loss: kr13.3m (down 176% from profit in 3Q 2021). Revenue is forecast to grow 79% p.a. on average during the next 3 years, compared to a 27% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 24Second quarter 2022 earnings released: kr0.45 loss per share (vs kr0.60 loss in 2Q 2021)Second quarter 2022 results: kr0.45 loss per share. Revenue: kr24.0k (up 100% from 2Q 2021). Net loss: kr17.9m (loss widened 29% from 2Q 2021).
Reported Earnings • May 13First quarter 2022 earnings: EPS misses analyst expectationsFirst quarter 2022 results: kr0.36 loss per share. Revenue: kr53.0k (down 87% from 1Q 2021). Net loss: kr14.2m (loss widened 3.7% from 1Q 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 6.2%.
Breakeven Date Change • Apr 27Forecast to breakeven in 2023The analyst covering Sprint Bioscience expects the company to break even for the first time. New forecast suggests the company will make a profit of kr5.00m in 2023. Average annual earnings growth of 79% is required to achieve expected profit on schedule.
Board Change • Apr 27High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Director Rune Nordlander is the most experienced director on the board, commencing their role in 2010. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 18Full year 2021 earnings: EPS misses analyst expectationsFull year 2021 results: kr0.85 loss per share (up from kr2.55 loss in FY 2020). Revenue: kr35.0m (up 83% from FY 2020). Net loss: kr25.1m (loss narrowed 41% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 6.2%. Over the next year, revenue is expected to shrink by 5.8% compared to a 216% growth forecast for the pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 17Full year 2021 earnings: EPS exceeds analyst expectationsFull year 2021 results: kr0.85 loss per share (up from kr2.55 loss in FY 2020). Revenue: kr35.1m (up 83% from FY 2020). Net loss: kr25.1m (loss narrowed 41% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 6.3%. Over the next year, revenue is expected to shrink by 5.9% compared to a 213% growth forecast for the pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.
Reported Earnings • Oct 29Third quarter 2021 earnings released: EPS kr0.54 (vs kr0.36 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr33.9m (up 399% from 3Q 2020). Net income: kr17.6m (up kr23.6m from 3Q 2020). Profit margin: 52% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Sep 15Director recently bought kr336k worth of stockOn the 10th of September, Rune Nordlander bought around 68k shares on-market at roughly kr4.95 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Reported Earnings • Aug 18Second quarter 2021 earnings released: kr0.60 loss per share (vs kr1.01 loss in 2Q 2020)The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: kr12.0k (down 100% from 2Q 2020). Net loss: kr13.9m (loss widened 11% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.
Reported Earnings • May 14First quarter 2021 earnings released: kr0.65 loss per share (vs kr0.79 loss in 1Q 2020)The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: kr408.0k (down 93% from 1Q 2020). Net loss: kr13.7m (loss widened 40% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings.
Executive Departure • Mar 03Interim Chief Executive Officer Charlotte Leife has left the companyOn the 1st of March, Charlotte Leife's tenure as Interim Chief Executive Officer of the company ended after less than a year in the role. We don't have any record of a personal shareholding under Charlotte's name. Charlotte is the only executive to leave the company over the last 12 months. Under Charlotte's leadership, the company delivered a total shareholder return of -0.9%.
Analyst Estimate Surprise Post Earnings • Feb 20Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 13%. Earnings per share (EPS) also surpassed analyst estimates by 39%. Over the next year, revenue is forecast to grow 62%, compared to a 126% growth forecast for the Biotechs industry in Sweden.
Is New 90 Day High Low • Feb 18New 90-day low: kr6.52The company is down 18% from its price of kr8.00 on 20 November 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period.
Reported Earnings • Feb 18Full year 2020 earnings released: kr2.02 loss per share (vs kr1.92 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: kr19.6m (down 42% from FY 2019). Net loss: kr42.8m (loss widened 99% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings.
Is New 90 Day High Low • Feb 02New 90-day low: kr7.10The company is down 7.0% from its price of kr7.60 on 03 November 2020. The Swedish market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 2.0% over the same period.
分析記事 • Nov 19Is Sprint Bioscience (STO:SPRINT) In A Good Position To Deliver On Growth Plans?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Reported Earnings • Nov 02Third quarter 2020 earnings released: kr0.36 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: kr6.79m (up 55% from 3Q 2019). Net loss: kr5.99m (loss narrowed 17% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 28% per year whereas the company’s share price has fallen by 32% per year.